The Canadian Intellectual Property Office has released a proposed new section of Chapter 17 (Biotechnology and Medicinal Inventions) of its Manual of Patent Office Practice (MOPOP), on the examination of pharmaceutical solid forms such as polymorphs, salts, hydrates, solvates, desolvates and co-crystals.
Consultation on the new MOPOP section is open until August 10, 2018.
Related Publications & Articles
-
Health Canada consultation on revised biosimilar guidance: no requirement for comparative clinical efficacy and safety trials
On June 10, 2025, Health Canada launched a consultation on its Draft Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs which includes numerous proposed revisions...Read More -
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
Health Canada must redetermine exemption requests for psilocybin (magic mushroom)-assisted psychotherapy training
TheraPsil, a patient advocacy organization, and 73 healthcare practitioners (HCPs) have succeeded in the Federal Court of Appeal to overturn the refusal of the Minister of Mental Health and Addictions...Read More